Results 241 to 250 of about 137,775 (303)

Treatment burden and health‐related quality of life in young adults with type 1 diabetes

Diabetic Medicine, EarlyView.
Abstract Aim This study aims to assess the treatment burden and health‐related quality of life (HRQoL) in young adults with type 1 diabetes (T1D). Methods Online survey on experienced treatment burden (Treatment Burden Questionnaire, TBQ, 0–150, higher scores indicate higher burden) and HRQoL (Type 1 Diabetes and Life questionnaire for ages 18–25 and ...
Anka Van Gastel, Matthijs Graner‐Baars, Anne M. Stiggelbout, Viet‐Thi Tran, Erik J. Giltay, Sean F. Dinneen, Jessica Mesman, Joris Swaak, Henk‐Jan Aanstoot, Victor M. Montori, Eelco J. P. De Koning, Marleen Kunneman   +11 more
wiley   +1 more source

Comparative predictive accuracy of machine learning versus traditional statistical methods for diabetes‐related complications: A systematic review and analysis

Diabetic Medicine, EarlyView.
This systematic review of 36 studies comparing machine learning with traditional statistical models for predicting diabetes‐related complications found modest discrimination gains with ensemble approaches, particularly random forest and gradient boosting.
Bismah Ghafoor, Francesco Zaccardi, Kamlesh Khunti, Sharmin Shabnam   +3 more
wiley   +1 more source

Detection of referable diabetic retinopathy using machine learning on routine clinical data. [PDF]

Front Med (Lausanne)
Jeon YJ, Song JS, Borghare S, Lee Y, Choi YW, Song J, Lim S, Woo SJ.   +7 more
europepmc   +1 more source

The impact of frailty on glycaemic control in older adults with type 1 diabetes: An observational study

Diabetic Medicine, EarlyView.
Abstract Aims The type 1 diabetes population is ageing. Frailty is the age‐related physiological decline that occurs across organ systems, increasing the body's vulnerability to stressors. Current consensus‐based guidelines, derived from evidence in type 2 diabetes, prioritise hypoglycaemia avoidance, which increases falls, hospitalisation and ...
Jonathan A. Golding, Scarlett O. Long, Suzy V. Hope, Juliet E. Wright, Ali J. Chakera, Tom J. Levett   +5 more
wiley   +1 more source

Exploring metabolomic clues in diabetic retinopathy: a pilot study. [PDF]

Acta Diabetol
Simonson M, Li Y, McAnany JJ, Park JC, Chau FY, Prasad B, Pannain S, Hanlon EC, Van Cauter E, Danielson KK, Layden BT, Chen H, Chlipala GE, Martinez C, Crowley SJ, Reutrakul S.   +15 more
europepmc   +1 more source

Diabetic Peripheral Neuropathy May Be an Independent Risk Marker for Dementia and Cerebrovascular Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Diabetic peripheral neuropathy (DPN) may be linked to central nervous system changes. This study examined if DPN is associated with an increased risk of incident dementia and cerebrovascular disease in individuals with Type 1 (T1D) and Type 2 diabetes (T2D). Materials and Methods This register‐based cohort study (1998–2020) used data from
Astrid Wiggers, Vanja Kosjerina, Malin Nilsson, Birgitte Brock, Steen Andersen, Evan L. Reynolds, Brian C. Callaghan, Eva L. Feldman, Jørgen Rungby, Christian Stevns Hansen   +9 more
wiley   +1 more source

Bumetanide‑blocked SLC12A2 exerts a protective effect in experimental diabetic retinopathy. [PDF]

Int J Mol Med
Zhang Y, Wang X, Xie Q, Huang Y, Huang D, Liu Z, Xu T, Ni M, Yang H.   +8 more
europepmc   +1 more source

Response to letter: ‘Towards equitable implementation of AI‐assisted screening for diabetic retinopathy: Perspectives on digital literacy, trust and system readiness in developing countries’

Diabetic Medicine, EarlyView.
Umar A. R. Chaudhry, Lakshmi Chandrasekaran, Alicja R. Rudnicka, On Behalf the ARIAS Research Group   +3 more
wiley   +1 more source

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the
Koutaro Yokote, Toshimasa Yamauchi, Yasushi Fukushima, Yoji Takatsuka, Marie Kato, Shijia Yan, Takayoshi Inoue, Luiza Borowska, Martina Brueckmann, Wataru Ogawa, on behalf of the SYNCHRONIZE‐JP Trial Investigators   +10 more
wiley   +1 more source